the t1/2 on tirzepatide is roughly 5 days, which means steady state takes about 4 to 5 weeks at any given dose. people keep titrating on the calendar (4 weeks up, 4 weeks up) without asking whether the drug has finished talking to them at the current dose. it usually hasn’t. what this means in practice: - week 1-2 on a new dose is mostly accumulation. side effects here are not the dose’s real signature, they’re the slope.
- week 3-4 is closer to steady state. this is when you actually learn what this dose does to your appetite, your nausea floor, your weight trajectory.
- if you’re still losing at week 4 on the current dose and tolerating it, moving up is buying problems you don’t need to buy yet. the SURMOUNT trials titrated on a fixed monthly schedule because that’s how you run a trial, not because the pharmacokinetics demand it. the protocol was a study design choice. people read it as a clinical recommendation and it isn’t quite that. the place i’d push back on myself: “hold longer” assumes your appetite suppression is durable at the current dose. for some people it isn’t, and the receptor downregulation conversation is real but underpowered in the published data. i don’t doubt the mechanism, i doubt the dose anyone needs to chase it. fwiw the compound vs brand question is mostly irrelevant to this. the molecule is the molecule. the titration logic doesn’t change based on where you sourced it. anyone holding longer than 4 weeks and tracking what happened? curious what week 6 or 8 on the same dose looked like for you.